DLL4 and pulmonary hypertension: Conversely, DLL4/NICD activation by olmesartan, an angiotensin II receptor blocker, attenuated transverse aortic constriction-induced cardiac remodeling in mice (13) and monocrotaline-induced pulmonary hypertension and right ventricular hypertrophy in rats (14).